Latest Oncology News

Active Clinical Trials of Interest in Endometrial Cancer Explore Novel Up-Front Approaches

Active Clinical Trials of Interest in Endometrial Cancer Explore Novel Up-Front Approaches

January 27th 2022

Ryan Scott

Bradley R. Corr, MD, discusses practice-changing developments and active clinical trials that are being done in endometrial cancer.

Modest Budget Effects Demonstrate Promise for Uptake of Genomic Profiling in NSCLC

Modest Budget Effects Demonstrate Promise for Uptake of Genomic Profiling in NSCLC

January 27th 2022

Brittany Lovely

The identification of actionable oncogenetic drivers in patients with non–small cell lung cancer affords clinicians the opportunity to use targeted agents to optimize outcomes.

2-Year OS Improves Over 20 Years in Relapsed Ph+ ALL Post Allogeneic Transplant

2-Year OS Improves Over 20 Years in Relapsed Ph+ ALL Post Allogeneic Transplant

January 27th 2022

Caroline Seymour

The 2-year overall survival rate almost doubled between 2000 and 2004 and 2015 and 2019 in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia who had relapsed after allogeneic hematopoietic cell transplant, indicating improvements in patient care overall.

Sorting Through Sexism, Guilt, and Motherhood in Medicine

Sorting Through Sexism, Guilt, and Motherhood in Medicine

January 27th 2022

OncLive Staff

Drs Garg, Outlaw-Evans, and Farrington discuss their experiences as women in oncology, changes they have observed in the culture of medicine, and their advice to young women entering the field.

UCLA Study Finds Combination Therapy Suppresses Pancreatic Tumor Growth in Mice

UCLA Study Finds Combination Therapy Suppresses Pancreatic Tumor Growth in Mice

January 27th 2022

UCLA Health Jonsson Comprehensive Cancer Center

UCLA Jonsson Comprehensive Cancer Center researchers have uncovered a potential new way to target pancreatic tumors that express high intratumoral interferon signaling

Latest Oncology Videos

All Oncology News

Rapid Readouts: Phase 2 CodeBreak 100 Trial

March 4th 2021

Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology

Alexander Spira, MD, PhD, FACP, presents slides from the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer (WCLC) from CodeBreak 100, the phase 2 trial of sotorasib in KRASG12C-mutated non–small cell lung cancer.

Dr. Philip on the Efficacy of TAS-102 in mCRC

March 4th 2021

Tony Philip, MD

Tony Philip, MD, discusses the efficacy of trifluridine/tipiracil in patients with metastatic colorectal cancer who are ineligible for intensive treatment.

FDA Expands Approval of Lorlatinib for Frontline ALK+ NSCLC

March 4th 2021

Kristi Rosa

The FDA has expanded the indication for lorlatinib to include the frontline treatment of patients with ALK-positive non–small cell lung cancer.

Dr. Wei on Benefits of Subcutaneous Pertuzumab/Trastuzumab in HER2+ Early Breast Cancer

March 3rd 2021

Mei Wei, MD

Mei Wei, MD, discusses the benefits of subcutaneous administration of pertuzumab and trastuzumab in patients with HER2-positive early breast cancer.

Dr. Shadman on the Role of MRD in CLL

March 3rd 2021

Mazyar Shadman, MD

Mazyar Shadman, MD, discusses the role of minimal residual disease in chronic lymphocytic leukemia.

Blinatumomab Significantly Prolongs EFS in Pediatric Relapsed B-ALL

March 3rd 2021

Treatment with 1 cycle of blinatumomab prior to transplant was found to result in a significant improvement in event-free survival vs standard intensive multidrug chemotherapy in pediatric patients with high-risk, first-relapse B-cell acute lymphoblastic leukemia.

Dr. Spira on the Challenges of Developing NRG1 Fusion–Directed Therapies in NSCLC

March 3rd 2021

Alexander Spira, MD, PhD, FACP

Alexander Spira, MD, PhD, FACP, discusses the challenges of developing targeted therapies for patients with NRG1 fusion–positive non–small cell lung cancer.

Dr. Borghaei on Unique Characteristics of EGFR Exon 20 Insertion Mutations in NSCLC

March 3rd 2021

Hossein Borghaei, DO

Hossein Borghaei, DO, MS, discusses unique characteristics of EGFR exon 20 insertion mutations in non–small cell lung cancer.

Dr. Grothey on Dosing Strategies With Regorafenib in CRC

March 3rd 2021

Axel Grothey, MD

Axel Grothey, MD, discusses dosing strategies with regorafenib in colorectal cancer.

Brown Breaks Down How to Choose the Optimal Frontline Approach for CLL

March 3rd 2021

Kristi Rosa

The treatment paradigm for chronic lymphocytic leukemia has expanded beyond continuous treatment with BTK inhibitors with the addition of the time-limited regimen of venetoclax plus obinutuzumab.

Presence of Pathogenic Variants Provide Rationale for Germline Sequencing in Pediatric Rhabdomyosarcoma

March 3rd 2021

Jessica Hergert

Pathogenic germline variants identified among children and young adults with rhabdomyosarcoma suggest that all children with RMS should undergo germline sequencing to utilize available surveillance guidelines and inform potential gene-specific therapy options.

FDA Grants Priority Review to Pafolacianine Sodium Injection in Ovarian Cancer

March 3rd 2021

Courtney Marabella

The FDA has granted priority review to the new drug application for the novel compound pafolacianine sodium injection for use in the identification of ovarian cancer during surgery.

Targeted DNA Sequencing Informs Posttransplant Relapse Rates in MDS

March 3rd 2021

Caroline Seymour

Targeted DNA sequencing prior to transplant can be used to determine which patients with myelodysplastic syndrome are at high risk for posttransplant relapse and should forego reduced-intensity conditioning in lieu of myeloablative conditioning.

Launch of ARANOTE Study Augments Development Program for Darolutamide in Prostate Cancer

March 3rd 2021

Caroline Seymour

Darolutamide plus ADT will be evaluated versus ADT alone in patients with metastatic hormone-sensitive prostate cancer in the phase 3 ARANOTE study as part Bayer and Orion Corporation’s growing clinical development program for the oral AR inhibitor in prostate cancer.

Bispecific Antibodies Could Be the Next Big Advance in Oncology

March 3rd 2021

OncLive Staff

Now, a new type of antibody-based therapy may overcome the limitations of monoclonal antibodies, and it has the potential to disrupt the current treatment paradigm in oncology.

See All News